---
title: "Aduro Biotech"
#date: '`r paste("Date:",Sys.Date())`'
fontsize: 12pt
output: html_document
---


<style type="text/css">

body{ /* Normal  */
      font-size: 13px;
  }
}
h1.title {
  font-size: 28px;
  color: DarkBlue;
}
h1 { /* Header 1 */
  font-size: 20px;
  color: DarkBlue;
}
h2 { /* Header 2 */
    font-size: 16px;
  color: DarkBlue;
}

}
code.r{ /* Code block */
    font-size: 12px;
}
pre { /* Code block - determines code spacing between lines */
    font-size: 14px;
}
</style>

\


# **Aduro Biotech (competitive strength):  **  
A biopharmaceutical company with three distinct immunotherapy technologies - STING pathway, B-select Antibodies, LADD.  


```{r setup, include=FALSE}
knitr::opts_chunk$set(echo = TRUE)
# can use it next time to add a pic by the title. don't need the R chunk.
#<script>
   #$(document).ready(function() {
     #$head = $('#header');
     #$head.prepend('<img src=\"logos.jpg\" style=\"float: right;width: 150px;\"/>')
   #});
#</script>

# the path problem: . means 当前project路径的同level的文件夹
```

# **Latest news about their STING Pathway (Apr 2018):  **  
*"For ADU-S100, we’ve confirmed in preclinical models that signaling through the STING pathway is critical to elicit tumor-reactive CD8+ T cells, the cornerstone of effective, durable and systemic anti-tumor immunity as evident from rejection of distant tumors. Importantly, these preclinical data show that adding checkpoint inhibitors to an ADU-S100 treatment regimen can eradicate tumors unresponsive to anti-PD-1 immunotherapy."*

*Proof of concept studies in syngeneic mouse models demonstrate that, the company's humanized anti-CTLA-4 monoclonal antibody (ADU-1604) further enhances anti-tumor activity when used in combination with ADU-S100 (also known as MIW815), Aduro’s lead investigational STING agonist, and in combination with Aduro’s proprietary immunotherapy platform of live-attenuated double-deleted Listeria monocytogenes strains (LADD).   *

#**Pipeline**  

<img src="timeline_pic.png" style="width:50%; height:70px">
<img src="./company_analysis_excel/Aduro.jpg" style="width:100%; height:600px">





For more details, check the reference below.



# Reference  
ADU-S100:    
http://www.aduro.com/pipeline/clinical-trials/   
https://www.clinicaltrials.gov/ct2/show/record/NCT02675439?term=NCT02675439&rank=1

ADU-S100 (with anti-PD1):  
https://www.clinicaltrials.gov/ct2/show/NCT02675439?term=NCT02675439&rank=1

Overall:  
http://www.aduro.com/file.cfm/125/docs/aduro_factsheet_v13.pdf  
http://investors.aduro.com/phoenix.zhtml?c=242043&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTEwMjA1NTc2JkRTRVE9MSZTRVE9MTA4JlNRREVTQz1TRUNUSU9OX1BBR0UmZXhwPSZzdWJzaWQ9NTc%3D  
https://www.sec.gov/Archives/edgar/data/1435049/000119312518005085/d520515dex991.htm
http://www.aduro.com/file.cfm/1/docs/Aduro_2017_AnnualReport.pdf
http://investors.aduro.com/phoenix.zhtml?c=242043&p=irol-newsArticle&ID=2316178


